Sunday, May 22, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Infectivity of SARS-CoV-2 Omicron variant in the intestinal tract

by Medical Finance
in Coronavirus
Study: Reduced replication efficacy of SARS-CoV-2 Omicron variant in “mini-gut” organoids. Image Credit: Explode/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study published in Gastroenterology, researchers assessed the infectivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in the intestinal tract.

Study: Reduced replication efficacy of SARS-CoV-2 Omicron variant in “mini-gut” organoids. Image Credit: Explode/Shutterstock
Study: Reduced replication efficacy of SARS-CoV-2 Omicron variant in “mini-gut” organoids. Image Credit: Explode/Shutterstock

Background

Coronavirus disease 2019 (COVID-19) is essentially a pulmonary disease due to SARS-CoV-2 infection of the respiratory tract. However, it can also proliferate in the intestinal tract. Of note, over 50% of COVID-19 patients exhibit SARS-CoV-2 shedding in their stools, indicated by the detection of SARS-CoV-2 in their feces. The SARS-CoV-2 Omicron and Delta strains replicate in the airways. However, the proliferation capabilities of the strains in intestinal organoids are unknown.

The authors of the present study previously reported that in induced pluripotent stem cells (iPS)-derived mini-gut (comprising various intestinal cells such as goblet-, epithelial-, enteroendocrine- and Paneth cells), epithelial cells lined the intestinal surface with stable expression of angiotensin-converting enzyme (ACE2) receptor and transmembrane protease serine 2 (TMPRSS2). ACE2 is essential for SARS-CoV-2 invasion of the host, and TMPRSS2 facilitates the viral entry. Thus, the previous findings indicated that the intestinal organoids are susceptible to SARS-CoV-2 infections.

About the study

In the present study, researchers investigated the susceptibility of the intestinal organoids to the SARS-CoV-2 prototype (Wuhan-hu-1), Omicron and Delta strains.

Two similar-sized organoids were cultured and inoculated with SARS-CoV-2 at a multiplicity of infection (m.o.i.) of 1. In parallel, cancer coli-2 (Caco-2), cultured human airway epithelial cells 3 (Calu-3), VeroE6, and VeroE6/TMPRSS2 cells were inoculated with SARS-CoV-2 at an m.o.i. of 0.05 for VeroE6 and VeroE6/TMPRSS2 and 0.5 for Caco-2 and Calu-3 cells.

Immunostaining was performed using SARS-CoV-2 nucleocapsid (NP) antibodies and the resultant images were evaluated eight days post-infection for staining of ACE2 and SARS-CoV-2 NP antigens.

In addition, the team assessed the effect of a neutralizing antibody cocktail (REGN-CoV-2, casirivimab, and imdevimab) in decreasing the viral cell-to-cell transmission. The supernatants obtained in the analysis were subjected to viral RNA quantification assays. Subsequently, viral titers were determined based on their cytopathic effects (CPE) and 50% tissue culture infectious dose (TCID50) values.

The secretion of lactate dehydrogenase (LDH) and the high mobility group box-1 (HMGB1) from the intestinal organoids was measured using cytotoxic assays and enzyme-linked immunosorbent assays (ELISA), respectively. Additionally, the levels of cytokines such as tumor necrosis factor-alpha (TNF-α) and interferons (IFN-β, λ3) in the culture supernatants of the mini-guts were quantified using ELISA.

Cell-based fusion assays were performed in which the donor cells [human embryonic kidney 293 (HEK293) cells expressing SARS-CoV-2 spike (S) and HiBiT] and acceptor cells [HEK293 cells expressing LgBiT and ACE2] were cultured simultaneously. Viral fusogenicity was determined based on their luciferase activity.

Findings

In this study, a peak was observed in SARS-CoV-2 replication after four days of infection. While Delta demonstrated a four-to-six-fold higher replication capacity compared to the prototype strain, the replication efficiency of Omicron was very low in Caco-2 cells, wherein Omicron shedding was remarkably low compared to the prototype and the Delta strains. Contrastingly, Omicron demonstrated replication efficiency comparable to the prototype strain in VeroE6 cells and Calu-3 cells, independent of TMPRSS2 expression.

LDH levels were substantially elevated in the prototype- and Delta-infected intestinal organoids, while those in mini-guts infected by Omicron were comparable to those in uninfected controls. Likewise, HMGB1 was expressed by the prototype- and Delta-infected intestinal organoids but not those infected by Omicron. On SARS-CoV-2 infection, HMGB1 is released, and subsequently, cytokines are produced. Thus, the study findings are indicative of the presence and absence of inflammatory potential of Delta and Omicron in the intestinal tract, respectively. This was underpinned by the increased cytokine levels in Delta-infected intestinal organoids compared to those infected by Omicron.

The immunostaining analysis showed that the mini-guts infected by the prototype strain demonstrated scattered cells with distinctive cell morphology, whereas the mini-guts infected by Delta demonstrated clusters of SARS-CoV-2-infected cells. This was indicative of the increased fusogenicity of Delta.

Omicron-infected mini-guts showed scarce SARS-CoV-2-infected cells. Of note, SARS-CoV-2 NP antigens were limited to the mini-gut epithelium’s luminal side, indicative of the low likelihood of SARS-CoV-2 invading the submucosa. Of interest, ACE2 expression was substantially downregulated in SARS-CoV-2-infected cells.

The antibody cocktail decreased lateral spreading of SARS-CoV-2, even two days post-Delta infection, thereby decreasing the clustering of SARS-CoV-2-infected cells. This was indicative of potential inhibition of SARS-CoV-2 spread by neutralizing antibodies in the mini-gut.

Conclusion

Overall, the study findings highlighted the selective reduction in Omicron infectivity in the mini-gut. However, further research is required to elucidate the mechanisms responsible for this reduction, which contrasts the high replication of Omicron in tissues such as the upper respiratory tract.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant. Image Credit: NIAID

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

by Medical Finance
May 22, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Within-host mathematical model provides insight into dynamics of SARS-CoV-2 infection

Within-host mathematical model provides insight into dynamics of SARS-CoV-2 infection

by Medical Finance
May 22, 2022
0

Several studies have been conducted to better understand the transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since...

Study: Intensity and longevity of SARS-CoV-2 vaccination response and efficacy of adjusted vaccination schedules in patients with immune-mediated inflammatory disease. Image Credit: Andreas Prott/Shutterstock

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

by Medical Finance
May 22, 2022
0

In a preprint version of a study posted on medRxiv*, researchers investigated the longevity and intensity of severe acute respiratory...

Study: 6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. Image Credit: Flowersandtraveling / Shutterstock.com

Antibody response to Pfizer-BioNTech COVID-19 vaccine over 6 months

by Medical Finance
May 22, 2022
0

The binding responses and temporal dynamics of antibodies elicited against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Study examines changes in postpartum insurance coverage in the U.S. during the COVID-19 pandemic

by Medical Finance
May 22, 2022
0

It's been the case for decades -; high numbers of U.S. women who give birth lose or face changes to...

Study: Prediction and validation of host cleavage targets of SARS-CoV-2 3C-like protease. ​​​​​​​Image Credit: NIAID

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

by Medical Finance
May 22, 2022
0

In an effort to better understand how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) selectively targets and damages specific...

Next Post
First patient-derived stem cell model developed for studying oculocutaneous albinism

New training scheme for convolutional neural networks automates cell segmentation and counting

Scientists identify a new switch for controlling motor proteins

Scientists discover how immune proteins defend plants against invading microorganisms

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model. Image Credit: Teeradej/Shutterstock
    Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious
  • 3d rendered illustration of sperms and an egg cell Sebastian Kaulitzki 2000 61f390311d3c4b1abeec7aceca5ab548 620x480
    Zebrafish model reveals how early embryo cells begin to independently produce proteins
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply